Dacomitinib (VizimproTM, PF-299804) is also an irreversible EGFR TKI that has been approved by the FDA to be used for patients with metastatic NSCLC with exon 19 deletion and exon 21 substitution [136,137,138,139]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.